Catalyst
Slingshot members are tracking this event:
Viamet's (Pending:VMET) VT-1161 Granted Qualified Infectious Disease Product (QIDP) Status for Fast Track Review by the FDA in Recurrent Yeast Infection
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| Viamet Pharmaceuticals |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 12, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Qualified Infectious Disease Product, Fast Track Review, Fda, Recurrent Vaginal Yeast Infection, Recurrent Vulvovaginal Candidiasis, Vt-1161
